Kestra Private Wealth Services LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,167 shares of the company’s stock after acquiring an additional 752 shares during the quarter. Eli Lilly and Company comprises 0.7% of Kestra Private Wealth Services LLC’s portfolio, making the stock its 23rd biggest holding. Kestra Private Wealth Services LLC’s holdings in Eli Lilly and Company were worth $66,147,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in LLY. Integrity Financial Corp WA increased its holdings in shares of Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares during the last quarter. LCM Capital Management Inc lifted its stake in shares of Eli Lilly and Company by 3.3% during the 3rd quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock worth $293,000 after buying an additional 8 shares during the last quarter. Smith Shellnut Wilson LLC ADV lifted its stake in shares of Eli Lilly and Company by 4.1% during the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock worth $235,000 after buying an additional 8 shares during the last quarter. Financial Network Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 5.6% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock worth $175,000 after buying an additional 8 shares during the period. Finally, Eads & Heald Wealth Management boosted its holdings in shares of Eli Lilly and Company by 0.5% during the 3rd quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company’s stock worth $1,700,000 after buying an additional 8 shares during the period. Institutional investors own 82.53% of the company’s stock.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
- Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
- Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Argus upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday, October 30th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Scotiabank boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada increased their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.
Read Our Latest Analysis on LLY
Insider Buying and Selling at Eli Lilly and Company
In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $17,020,770 in the last ninety days. 0.14% of the stock is currently owned by company insiders.
Eli Lilly and Company Stock Performance
LLY opened at $1,368.85 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.43, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The business’s fifty day moving average is $1,211.30 and its 200-day moving average is $1,099.50.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the previous year, the firm earned $7.02 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. Sell-side analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
